CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Amendment No. 2 to Amended...Royalty Pharma PLC • November 5th, 2020 • Pharmaceutical preparations
This Amendment No. 2 (“Amendment No. 2”) to the Amended and Restated Purchase and Sale Agreement dated as of November 24, 2014, as amended by Amendment No. 1 (“Amendment No. 1”) dated October 13, 2016 (as amended, the “Purchase and Sale Agreement”), is entered into on this 30th day of October 2020 (the “Amendment No. 2 Effective Date”) by and between Cystic Fibrosis Foundation, a Delaware non-stock corporation (the “Seller”) (as successor in interest to Cystic Fibrosis Foundation Therapeutics, Inc. (“CFFT”)), RPI Finance Trust (the “Purchaser”) and RPI 2019 Intermediate Finance Trust (“RPI 2019 IFT”). Capitalized terms not defined herein have the meanings assigned to them in the Purchase and Sale Agreement.
